BIOCYTOGEN-B (02315) has completed the localization deployment of the DeepSeek platform, upgrading the "A Thousand Mice, Ten Thousand Antibodies" antibody drug development strategy.

Announcement of Biocytogen-B (02315): the company has recently completed the localization deployment of its artificial intelligence (AI) driven antibody drug development platform DeepSeek, and achieved comprehensive synergy with the company's core business "Thousand Mice, Ten Thousand Antibodies" plan. This technical integration marks a new stage of intelligence and dataization in the early development of antibody drugs, and will provide more precise and groundbreaking antibody drug development solutions for global pharmaceutical companies in the future, significantly accelerating the drug development process. Biocytogen launched the "Thousand Mice, Ten Thousand Antibodies" plan in 2020, targeting over 1,000 potential antibody drug targets, conducting antibody development on the company's self-developed RenMab, RenLite, and RenNano humanized antibody mouse platforms. Currently, the company has obtained over 500,000 humanized antibody sequence molecules targeting over 1,000 drug targets, covering various forms of antibody molecules including monoclonal antibodies, bispecific antibodies, and nanobodies, with high affinity, low immunogenicity, and drug-like advantages. The humanized antibody molecule library will quickly grow to tens of millions in the future. Biocytogen recognizes the enormous potential of AI in antibody drug development and has deployed the DeepSeek platform locally ahead of others. With the DeepSeek platform, AI algorithms can empower the massive real antibody molecule library of the "Thousand Mice, Ten Thousand Antibodies" plan, avoiding common "AI illusions." Through the combination of the "Thousand Mice, Ten Thousand Antibodies" antibody molecule library and the DeepSeek platform, Biocytogen can provide global pharmaceutical companies with new monoclonal, bispecific, and multispecific molecular frameworks. These molecular frameworks have high affinity, low immunogenicity, and excellent drug-like properties. With the help of the DeepSeek platform, global pharmaceutical companies can quickly screen out target antibody molecules with high drug potential from the real existing tens of millions antibody molecule library of the "Thousand Mice, Ten Thousand Antibodies." DeepSeek can also identify molecular frameworks through simulated molecular interactions and screen for specific functional multispecific antibodies such as bispecific and multispecific antibodies, rapidly develop innovative antibody drugs for various diseases, greatly accelerate the drug development process, and meet unmet clinical needs. In the future, with the deep integration of the "Thousand Mice, Ten Thousand Antibodies" and DeepSeek, Biocytogen will provide more efficient research and development tools and a more extensive antibody molecule library for global pharmaceutical companies, promoting the rapid development of antibody drugs. With further development and application of AI technology, revolutionary changes are expected in antibody drug development. Biocytogen will continue to delve into this innovative field, collaborate with global partners, and collectively provide more efficient and safe treatment options for patients worldwide.